PASITHEA THERAPEUTICS CORP

Company Overview

Pasithea Therapeutics is a clinical-stage biotechnology company focused on small molecules and biologics that target MAPK-driven diseases, RASopathies and CNS disorders. Its lead candidate, PAS‑1004, is a novel macrocyclic allosteric MEK1/2 inhibitor with FDA orphan designation for NF1‑associated plexiform neurofibromas (NF1‑PN), an IND cleared in December 2023, an ongoing FIH Phase 1 dose‑escalation study (17 patients dosed through cohort 4 so far) and planned Phase 1/1b NF1‑PN adult enrollment. The company runs a single therapeutics segment, outsources CMC and clinical supply (WuXi/WuXi STA), maintains a very small headcount and has no product revenue; near‑term value drivers are clinical readouts, regulatory milestones and securing additional financing to extend runway.

Executive Compensation Practices

As a small, clinical‑stage biotech in the Biotechnology/Pharmaceutical Products sector, Pasithea’s pay programs are likely equity‑heavy with modest cash salaries and significant stock‑based incentives to align management with long‑dated clinical and regulatory goals. The 10‑K/MD&A notes higher stock‑based compensation year over year and management uses Black‑Scholes for grant valuation, indicating reliance on options/RSUs and milestone‑linked awards tied to INDs, cohort completions, PD/safety readouts and business development or partnering events. Given constrained cash and need for retention during critical clinical ramp, compensation packages may include milestone bonuses, accelerated vesting triggers on financing/partnership events, and occasionally supplemental cash or consulting arrangements for key hires.

Insider Trading Considerations

Pasithea’s small public float, recent reverse split, limited working capital and explicit near‑term liquidity needs create a high probability of insider participation in financings (equity offerings, ATM programs, warrant exercises) and opportunistic selling to cover tax liabilities from option exercises. Recent activity (May 2025 public offering, ATM sales and warrant exercises) demonstrates these patterns; monitor Form 4 filings for option exercises, open‑market sales and participation in block placements. Trading is also likely to cluster around clinical milestones and regulatory disclosures (INDs, cohort safety/PK/PD readouts), so watch blackout windows, any disclosed Rule 10b5‑1 plans, and Nasdaq reporting/noncompliance notices which can change timing and size of insider transactions.